These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 5456013)

  • 1. Amphotericin B serum concentrations during therapy.
    Fields BT; Bates JH; Abernathy RS
    Appl Microbiol; 1970 Jun; 19(6):955-9. PubMed ID: 5456013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rapid intravenous infusion on serum concentrations of amphotericin B.
    Fields BT; Bates JH; Abernathy RS
    Appl Microbiol; 1971 Oct; 22(4):615-7. PubMed ID: 5130433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections.
    Sculier JP; Coune A; Meunier F; Brassinne C; Laduron C; Hollaert C; Collette N; Heymans C; Klastersky J
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):527-38. PubMed ID: 3383959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for the treatment of generalized mycoses with amphotericin B].
    Rieth H
    Mykosen; 1967 Jan; 10(1):31-2. PubMed ID: 5589759
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy of systemic mycoses (first of two parts).
    Bennett JE
    N Engl J Med; 1974 Jan; 290(1):30-2. PubMed ID: 4593887
    [No Abstract]   [Full Text] [Related]  

  • 6. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid.
    Jorgensen JH; Alexander GA; Graybill JR; Drutz DJ
    Antimicrob Agents Chemother; 1981 Jul; 20(1):59-62. PubMed ID: 6269483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioassay for hamycin and amphotericin B in serum and other biological fluids.
    Shadomy S; McCay JA; Schwartz SI
    Appl Microbiol; 1969 Apr; 17(4):497-503. PubMed ID: 5814426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of deep mycoses with liposomal amphotericin B.
    Berenguer J; Muñoz P; Parras F; Fernández-Baca V; Hernández-Sampelayo T; Bouza E
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):504-7. PubMed ID: 7957273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amphotericin B and its lipid formulations].
    Ritter J
    Mycoses; 2002; 45 Suppl 3():34-8. PubMed ID: 12690969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of systemic antifungal therapy.
    Summers KK; Hardin TC; Gore SJ; Graybill JR
    J Antimicrob Chemother; 1997 Dec; 40(6):753-64. PubMed ID: 9462426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a correlation between serum antifungal drug concentration and clinical outcome?
    Graybill JR
    J Infect; 1994 May; 28 Suppl 1():17-24. PubMed ID: 8077687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B--specifics of administration.
    Goodman JS; Koenig MG
    Mod Treat; 1970 May; 7(3):581-95. PubMed ID: 4920806
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)].
    Maniwa T; Yamamoto Y
    Nihon Yakurigaku Zasshi; 2007 Feb; 129(2):129-34. PubMed ID: 17299241
    [No Abstract]   [Full Text] [Related]  

  • 14. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
    Viscoli C; Castagnola E
    Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.
    Perfect JR; Durack DT
    Antimicrob Agents Chemother; 1985 Dec; 28(6):751-5. PubMed ID: 4083860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacologic guide to the clinical use of amphotericin B.
    Bindschadler DD; Bennett JE
    J Infect Dis; 1969 Oct; 120(4):427-36. PubMed ID: 5394441
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.
    Baley JE; Meyers C; Kliegman RM; Jacobs MR; Blumer JL
    J Pediatr; 1990 May; 116(5):791-7. PubMed ID: 2329429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current role of therapy with amphotericin B.
    Meyer RD
    Clin Infect Dis; 1992 Mar; 14 Suppl 1():S154-60. PubMed ID: 1562689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B enzyme-linked immunoassay for clinical use: comparison with bioassay and HPLC.
    Cleary JD; Chapman SW; Hardin TC; Rinaldi MG; Spencer JL; Deng J; Pennick GJ; Lobb CJ
    Ann Pharmacother; 1997 Jan; 31(1):39-44. PubMed ID: 8997463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.